Induction Chemotherapy for Locoregionally Advanced Sinonasal Squamous Cell Carcinoma
Journal of Neurological Surgery Part B: Skull Base · 01.10.2024 · 85 (S 02 S 02) · e153-e160
DOI: 10.1055/a-2226-8414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurological Surgery Part B: Skull Base, erschienen am 01.10.2024. Verfasst von Arash Abiri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
There is emerging evidence to suggest the role of induction chemotherapy (IC) in definitive management of locoregionally advanced sinonasal squamous cell carcinoma (SNSCC). We evaluated the influence of IC on survival and predictors of its use in SNSCC patients.
Methods
The 2004 to 2017 National Cancer Database was queried for patients with locoregionally advanced SNSCC (T4/M0). Treatments were stratified into seven groups: definitive chemoradiation (CRT), IC with definitive CRT (IC + CRT), IC + CRT with salvage surgery (IC + CRT + Sx), definitive surgery (Sx), IC with definitive surgery (IC + Sx), definitive surgery with adjuvant radiation or CRT (Sx + ATx), or IC + Sx + ATx. Cox proportional-hazards regression assessed overall survival (OS) and logistic regression identified predictors of IC.
Results
Of 3,162 patients, 1,088 (34.4%) were female with a mean age of 63.4 ± 13.4 years. The 2- and 5-year OS rates were 58.6 and 42.0%, respectively. Compared with CRT, Sx + ATx (hazard ratio [HR]: 0.663; p < 0.001), IC + Sx (HR: 0.606; p = 0.005), or IC + Sx + ATx (HR: 0.468; p = 0.001) exhibited reduced mortality. Among patients who were treated with definitive surgery, those receiving IC had additional OS benefit (all ps < 0.05). Older age (odds ratio [OR]: 0.607; p < 0.001), female sex (OR: 0.759; p = 0.028), Black race (OR: 1.650; p < 0.001, T4b stage (OR: 1.674; p < 0.001), and higher N stage (OR: 1.395; p < 0.001) were predictors of IC.
Conclusion
IC prior to definitive surgery with or without adjuvant therapy exhibited the highest OS for locoregionally advanced SNSCC. Age, sex, race, and T/N staging were predictors of IC. Multimodal treatment regimens involving surgery as the primary modality may, therefore, provide the greatest therapeutic response.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California, United States.
- Department of Neurological Surgery, University of California, Irvine, Orange, California, United States.
ORCID-Profile: Arash Abiri, Jonathan C Pang
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Abiri, A., Liu, D. H., Nguyen, T. V., Pang, J. C., Torabi, S. J., & Kuan, E. C. (2024). Induction Chemotherapy for Locoregionally Advanced Sinonasal Squamous Cell Carcinoma. Journal of Neurological Surgery Part B: Skull Base, 85(S 02 S 02), e153-e160. https://doi.org/10.1055/a-2226-8414
Vancouver
Abiri A, Liu DH, Nguyen TV, Pang JC, Torabi SJ, Kuan EC. Induction Chemotherapy for Locoregionally Advanced Sinonasal Squamous Cell Carcinoma. Journal of Neurological Surgery Part B: Skull Base. 2024;85(S 02 S 02):e153-e160. doi:10.1055/a-2226-8414
BibTeX
@article{Abiri2024,
author = {Abiri, Arash and Liu, Derek H and Nguyen, Theodore V and Pang, Jonathan C and Torabi, Sina J and Kuan, Edward C},
title = {Induction Chemotherapy for Locoregionally Advanced Sinonasal Squamous Cell Carcinoma},
journal = {Journal of Neurological Surgery Part B: Skull Base},
year = {2024},
volume = {85},
number = {S 02 S 02},
pages = {e153--e160},
doi = {10.1055/a-2226-8414}
}
EUVIMED